Giorgio Luciano Viviani

Giorgio Luciano Viviani

Auto-generated profile, based on publicly available information

Giorgio Luciano Viviani

Department of Internal Medicine, Adult Diabetes Centre, University of Genoa, Italy

Research Focus & Metrics

Academic Career Length

49Years (1978-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 1990 in Acta Diabetologica
Verified
Journal Article
Closed access
PDF file
Camillo  RicordiCamillo Ricordi
Camillo Ricordi
DGDerek W. R. Gray
Derek W. R. Gray
BHBernhard J. Hering
Bernhard J. Hering
DKDixon B. Kaufman
Dixon B. Kaufman
GWGarth L. Warnock
Garth L. Warnock
PLPaul E. Lacy
Paul E. Lacy

1 January 2012 in World Journal of Gastroenterology
Verified
Journal Article
Open access
VBVincent Braunersreuther
Vincent Braunersreuther
GVGiorgio Luciano Viviani
Giorgio Luciano Viviani
FMFrançois Mach
François Mach
Fabrizio MontecuccoFabrizio Montecucco
Fabrizio Montecucco
Non-alcoholic fatty liver disease (NAFLD) includes a variety of histological conditions (ranging from liver steatosis and steatohepatitis, to fibrosis and hepatocarcinoma) that are characterized by an increased fat content within the liver. The accumulation/deposition of fat within the liver is essential for diagnosis of NAFLD and might be associated with alterations in the hepatic and systemic inflammatory state. Although it is still unclear if each histological entity represents a different disease or rather steps of the same disease, inflammatory processes in NAFLD might influence its pathophysiology and prognosis. In particular, non-alcoholic steatohepatitis (the most inflamed condition in NAFLDs, which more frequently evolves towards chronic and serious liver diseases) is characterized by a marked activation of inflammatory cells and the upregulation of several soluble inflammatory mediators. Among several mediators, cytokines and chemokines might play a pivotal active role in NAFLD and are considered as potential therapeutic targets. In this review, we will update evidence from both basic research and clinical studies on the potential role of cytokines and chemokines in the pathophysiology of NAFLD.

1 January 2014 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
APAlessandra Puddu
Alessandra Puddu
RSRoberta Sanguineti
Roberta Sanguineti
Fabrizio MontecuccoFabrizio Montecucco
Fabrizio Montecucco
GVGiorgio Luciano Viviani
Giorgio Luciano Viviani
In type 2 diabetes, hyperglycemia, insulin resistance, increased inflammation, and oxidative stress were shown to be associated with the progressive deterioration of beta-cell function and mass. Short-chain fatty acids (SCFAs) are organic fatty acids produced in the distal gut by bacterial fermentation of macrofibrous material that might improve type 2 diabetes features. Their main beneficial activities were identified in the decrease of serum levels of glucose, insulin resistance as well as inflammation, and increase in protective Glucagon-like peptide-1 (GLP-1) secretion. In this review, we updated evidence on the effects of SCFAs potentially improving metabolic control in type 2 diabetes.

1 January 2011 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Closed access
VSV. Spallone
V. Spallone
FBF. Bellavere
F. Bellavere
LSL. Scionti
L. Scionti
SMS. Maule
S. Maule
RQR. Quadri
R. Quadri
RMR. Morganti
R. Morganti

1 January 2011 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
GVGiorgio Luciano Viviani
Giorgio Luciano Viviani
FDFranco Dallegri
Franco Dallegri
AQAlessandra Quercioli
Alessandra Quercioli
EVEdvige Veneselli
Edvige Veneselli
FMFrançois Mach
François Mach
Fabrizio MontecuccoFabrizio Montecucco
Fabrizio Montecucco
Summary: The definition of ischaemic stroke has been recently updated as an acute episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischaemia in the presence of a cerebral infarction. This “tissular” definition has highlighted the importance of pathophysiological processes underlying cerebral damage. In particular, post-ischaemic inflammation in the brain and in the blood stream could influence crucial steps of the tissue injury/repair cascade. CC and CXC chemokines orchestrate the inflammatory response in atherosclerotic plaque vulnerability and cerebral infarction. These molecules exert their activities through the binding to selective transmembrane receptors. CC and CXC chemokines modulate crucial processes (such as inflammatory cell recruitment and activation, neuronal survival, neoangio-genesis). On the other hand, CXC chemokines could also modulate stem cell homing, thus favouring tissue repair. Given this evidence, both CC and CXC chemokines could represent promising therapeutic targets in primary and secondary prevention of ischaemic stroke. Only preliminary studies have been performed investigating treatments with selective chemokine agonists/antagonists. In this review, we will update evidence on the role and the potential therapeutic strategies targeting CC and CXC chemokines in the pathophysiology of ischaemic stroke.

1 January 2014 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
RSRoberta Sanguineti
Roberta Sanguineti
APAlessandra Puddu
Alessandra Puddu
FMFrançois Mach
François Mach
Fabrizio MontecuccoFabrizio Montecucco
Fabrizio Montecucco
GVGiorgio Luciano Viviani
Giorgio Luciano Viviani
Osteoporosis is a major public health burden that is expected to further increase as the global population ages. In the last twenty years, advanced glycation end products (AGEs) have been shown to be critical mediators both in the pathogenesis and development of osteoporosis and other chronic degenerative diseases related to aging. The accumulation of AGEs within the bone induces the formation of covalent cross-links with collagen and other bone proteins which affects the mechanical properties of tissue and disturbs bone remodelling and deterioration, underlying osteoporosis. On the other hand, the gradual deterioration of the immune system during aging (defined as immunosenescence) is also characterized by the generation of a high level of oxidants and AGEs. The synthesis and accumulation of AGEs (both localized within the bone or in the systemic circulation) might trigger a vicious circle (in which inflammation and aging merged in the word “Inflammaging”) which can establish and sustain the development of osteoporosis. This narrative review will update the molecular mechanisms/pathways by which AGEs induce the functional and structural bone impairment typical of osteoporosis.